Oral propionyl-L-carnitine and intraplaque verapamil in the therapy of advanced and resistant Peyronie's disease

Objective To ascertain whether oral propionyl-L-carnitine combined with intraplaque verapamil is a useful therapy for advanced or resistant Peyronie's disease. Patients and methods The combined drugs were assessed in two studies. In the first, 60 patients with advanced Peyronie's disease, diagnosed using accepted definitions. were randomized in two subgroups treated with verapamil intraplaque infiltration (10 mg weekly for 10 weeks) plus a 3-month administration of propionyl-L-carnitine (2 g/day), or verapamil infiltration plus oral tamoxifen (40 mg/day) for 3 months. In the second study, 15 patients with resistant Peyronie's disease (progression despite previous therapy) received verapamil plus propionyl-L-carnitine. The differences between subgroups or between the variables before and after therapy were compared using analysis of variance or the chi-squared test. Results In the first study. the reduction in pain was the same in both subgroups. Propionyl-L-carnitine plus verapamil significantly reduced penile curvature, plaque size, cavernosal artery end-diastolic velocity, the need for surgery and disease progression, and increased the International Index of Erectile Function score and resistivity index of the cavernosal arteries. Tamoxifen Plus verapamil had none of these effects. No drug combination affected the peak systolic velocity. Patients receiving verapamil had no side-effects but those taking tamoxifen did. In the second study propionyl-L-carnitine and verapamil modified the disease patterns as in the first and no patient had side-effects. Conclusion The combination of propionyl-L-carnitine and verapamil can be considered the therapy of choice for advanced and resistant Peyronie's disease.